Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 9th Conference on Retroviruses and Opportunistic Infections
Antiretroviral Chemotherapy: New Agents (Oral Abstract Session 4)

February 25, 2002

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

  • TMC125 Monotherapy for 1 Week Results in a Similar Initial Rate of Decline of HIV-1 RNA as Therapy With a Five-Drug Regimen
    Abstract 5
    Authored by S. Sankatsing1, G. Weverling1, G. van't Klooster2, J. Prins1, and J. Lange1 (1Univ. of Amsterdam, The Netherlands, and 2Tibotec-Virco NV, Mechelen, Belgium)
    View the original abstract


Increasing the potency of antiretroviral therapy remains an important goal of drug development, as there is still evidence of residual viral replication even in patients with "suppressed" viral loads. To that end, there has been considerable excitement about TMC125, an investigational NNRTI being developed by the Belgian company Tibotec. Following up on the seven-day monotherapy study presented at ICAAC -- where a mean 1.99 log viral load reduction was demonstrated -- J. Lange today compared this impressive viral load response with that obtained from a five-drug regimen.

The comparator regimen was chosen from the previously-conducted ERA study, and consisted of AZT/3TC/abacavir/indinavir/nevirapine; results were published in the journal AIDS in 1998. In this study, early viral load measurements were done at days 0, 1, 3, 4, and 7, versus daily in the TMC125 study. Compared with the TMC125 study group, at baseline those in the ERA study were older and had slightly higher baseline viral loads and lower CD4 cell counts.

Based on the seven-day measurements, the following results were obtained:


 

ERA Study (5 Drugs)TMC125
Median viral load reduction, day seven1.761.92
Median virion clearance rate constant0.560.68
Median CD4 cell count increase60119


None of the above differences between the five-drug ERA regimen and TMC125 were statistically significant.

Although cross-study comparisons should be made cautiously, these data underscore the robust antiviral activity of TMC125 in drug-naive patients, achieving at seven days results comparable to a five-drug regimen. As noted in Abstract 4, TMC125 also has activity (albeit somewhat lower in magnitude) in most patients who have experienced virologic failure to NNRTIs. The excitement about TMC125's ongoing development must be tempered somewhat by the drug's currently unpalatable formulation, which requires ingestion of 18 tablets twice daily! On an encouraging note, Tibotec is actively pursuing a more user-friendly formulation, one that will significantly reduce this pill burden.


A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

See Also
More on HIV Medications
More News and Research on Etravirine (Intelence)



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement